Table 1.
Patient Characteristics
| Characteristic | XRT (n = 47) | C/CMT (n = 181) | P (XRT v C/CMT) | De Novo (n = 222) | P (XRT v De Novo) |
|---|---|---|---|---|---|
| Demographics | |||||
| Sex | .03* | 0.3* | |||
| Male | 31 | 88 | 127 | ||
| Female | 16 | 93 | 95 | ||
| Age, years | < .001† | .001† | |||
| Median | 74 | 65 | 66 | ||
| Range | 40-87 | 14-88 | 18-93 | ||
| Latency, months | .9* | NA | NA | ||
| Median | 60 | 57 | |||
| Range | 8-462 | 6-360 | |||
| Reason for prior therapy‡ | < .001§ | .001§ | |||
| No prior therapy | 0 | 0 | 197 | ||
| Breast cancer | 15 | 29 | 1 | ||
| GI cancer | 0 | 9 | 3 | ||
| Genitourinary cancer | 2 | 7 | 3 | ||
| Gynecologic cancer | 0 | 12 | 2 | ||
| Head and neck cancer | 4 | 6 | 1 | ||
| Lymphoma or myeloma | 2 | 87 | 2 | ||
| Lung cancer | 0 | 5 | 1 | ||
| Prostate cancer | 24 | 5 | 11 | ||
| Melanoma | 0 | 2 | 1 | ||
| Other neoplasms | 0 | 12 | 0 | ||
| Other nonneoplastic | 0 | 7 | 0 |
Abbreviations: C/CMT, cytotoxic chemotherapy/combined-modality therapy; XRT, external-beam radiation therapy; NA, not applicable.
*
Two-sample test of proportions.
†
Pearson's test of medians with continuity correction.
‡
In the de novo group, this denotes prior malignancies treated with surgery only or noncytotoxic therapy (such as monoclonal antibodies).
§
Fisher's exact test.